
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
Kenneth J. Martin, Wyeth's (Madison, NJ, www.wyeth.com) chief financial officer and vice chairman, has announced plans to leave the company at the end of June.
Kenneth J. Martin, Wyeth’s (Madison, NJ,







